For the third quarter ended Dec. 31, 2008, Zydus Cadila, a parent firm of Cadila Healthcare registered a total income of Rs 7.59 billion up by 31% from Rs 5.80 billion in the corresponding period last year, on a consolidated basis.
The net profit after tax stood at Rs 610 million up by 17% from Rs 520 million, during the same period last year. This was after providing for the exchange rate fluctuation loss of Rs 110 million on conversion of foreign currency loans during the quarter, vis-a-vis gain of Rs 60 million during the same period last year. During the quarter, the income growth was mainly driven by formulation exports which registered a growth of 61%. The company`s subsidiaries in the US and Brazil registered a strong performance. In the US, the company posted sales of Rs 1.07 billion during the quarter, up by 87%. The group filed 2 more Abbreviated New Drug Application (ANDAs) and 4 additional DMFs this quarter, taking the total to 80 ANDA filings and 71 Drug Master File (DMFs). The group has received 41 product approvals so far. In Brazil, the company registered sales of Rs 470 million during the quarter, up by 41%. Exports to other emerging markets grew by 95% and posted sales of Rs 470 million. During the quarter, the composite scheme of arrangement to restructure the consumer business of the group was approved by the hon`ble high court of Gujarat. With this, the consumer business of Cadila Healthcare was integrated into Carnation Nutra Analogue, and subsequently renamed as Zydus Wellness. For the quarter, the consumer business on a consolidated basis grew by 24% Providing a fillip to the group`s status as one of the largest producers of rabies vaccine in India, the World Health Organization (WHO) approved Lyssavac N - the Purified Duck Embryo Rabies Vaccine (PDEV) manufactured by it, for purchase by various United Nations Agencies. With this, Zydus Cadila became the first Indian Pharma company and the second pharma company in the world, to receive the WHO accreditation (prequalification) for rabies vaccine. Currently, the group produces 3 million doses of the rabies vaccine per annum. Shares of Cadila Healthcare gained Rs 6.1, or 2.56%, to settle at Rs 244.80. The total volume of shares traded was 28,197 at the BSE (Tuesday). --~--~---------~--~----~------------~-------~--~----~ You received this message because you are subscribed to the Google Groups "Kences1" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [email protected] For more options, visit this group at http://groups.google.com/group/kences1?hl=en -~----------~----~----~----~------~----~------~--~---
